

UROPLASTY INC
Form DEFA14A
March 10, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Uroplasty, Inc.

(Name of Registrant as Specified In Its Charter)

Not Applicable

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the
(3) amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 240.0-11 and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



The following is a letter sent to certain Uroplasty shareholders by Uroplasty, Inc. on March 10, 2015:

Uroplasty, Inc.
5420 Feltl Road
Minnetonka, MN 55343 USA
Toll free 866 258 2182
Fax 952 426 6199
www uroplasty.com

March 10, 2015

Dear Fellow Shareholder:

I am writing you concerning the Special Meeting of Uroplasty Shareholders, which is scheduled for Monday, March 30, 2015, and am asking you to vote "FOR" the approval of the proposed merger of Uroplasty and Vision-Sciences to form a new company to be named Cogentix Medical.

Your Board of Directors has unanimously recommended that Uroplasty shareholders vote "FOR" the approval of the agreement and plan of merger between Uroplasty and Vision-Sciences and the other matters described in the joint proxy statement/prospectus which we sent to you on or about February 26, 2015. I strongly encourage you to review the proposals for our Special Shareholders Meeting and the other disclosures contained in the joint proxy statement/prospectus.

Records indicate that we have not yet received your vote. Please take action now to vote your Uroplasty shares by signing, dating and returning the enclosed proxy voting instruction form card in the envelope provided.

If you hold your shares at a bank or brokerage firm, you also have the option to vote via either telephone or internet, by following the enclosed instructions.

If you have any questions about voting your shares, you may also contact The Proxy Advisory Group, LLC, which is assisting us in this matter, by calling toll-free to 888-33PROXY, or 888-337-7699

Your vote is very important, regardless of the number of Uroplasty shares you own. Please take action to vote today. Thank you for giving this important matter on our company your immediate attention.

Sincerely,

/s/ Rob Kill

Rob Kill
President and CEO
Uroplasty, Inc.
